版本:
中国

BRIEF-Contravir Pharmaceuticals CMX157 advances head-to-head Phase 2a clinical study

Oct 17 Contravir Pharmaceuticals Inc

* CMX157 advances head-to-head phase 2A clinical study in Hepatitis B patients with favorable recommendation from DSMB

* Contravir expects to complete remaining two escalation cohorts and report top-line results by year-end 2016.

* Contravir Pharmaceuticals - begun enrolling next dosing group in hephase 2A dose-escalation study comparing safety and efficacy of contravir's CMX157 to tenofovir disoproxil fumarate Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐